Ruxolitinib (BioDeep_00000648583)
代谢物信息卡片
Ruxolitinib
化学式: C17H18N6 (306.1592868)
中文名称: 鲁索利替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
InChI: InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
描述信息
D - Dermatologicals > D11 - Other dermatological preparations > D11A - Other dermatological preparations > D11AH - Agents for dermatitis, excluding corticosteroids
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EJ - Janus-associated kinase (jak) inhibitors
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
COVID info from Guide to PHARMACOLOGY, clinicaltrial, clinicaltrials, clinical trial, clinical trials
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C172200 - JAK Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C125450 - JAK2 Inhibitor
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
1 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:66919
- KEGGdrug: D09959
- PubChem: 25126798
- DrugBank: DB08877
- ChEMBL: CHEMBL1789941
- CAS: 1092939-15-5
- CAS: 941678-49-5
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- G M Li, Y B Jin, Y Z Gan, C Chen, Y Jia, C Li. [Ruxolitinib as an effective treatment for panniculitis associated hemophagocytic syndrome: A report of 2 cases and literature review].
Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences.
2022 Dec; 54(6):1208-1213. doi:
. [PMID: 36533357] - Zhuo Li, Ning Sun, Qing Zhang, Hong-Hao Ma, Dong Wang, Yun-Ze Zhao, Chang-Qing Yang, Rui Zhang, Li-Bo Zhao. Development and application of an LC-MS/MS method for pharmacokinetic study of ruxolitinib in children with hemophagocytic lymphohistiocytosis.
Analytical methods : advancing methods and applications.
2022 06; 14(23):2293-2303. doi:
10.1039/d2ay00533f. [PMID: 35635540] - Shirin Hasan, Liping Hu, Olatundun Williams, Elizabeth A Eklund. Ruxolitinib ameliorates progressive anemia and improves survival during episodes of emergency granulopoiesis in Fanconi C-/- mice.
Experimental hematology.
2022 05; 109(?):55-67.e2. doi:
10.1016/j.exphem.2022.03.001. [PMID: 35278531] - Robert Bissonnette, Robert S Call, Tooraj Raoof, Zhaoyin Zhu, Swamy Yeleswaram, Xiaohua Gong, Mark Lee. A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis.
American journal of clinical dermatology.
2022 May; 23(3):355-364. doi:
10.1007/s40257-022-00690-3. [PMID: 35368221] - Giuseppe Auteri, Daniela Bartoletti, Christian Di Pietro, Emanuele Sutto, Camilla Mazzoni, Andrea Davide Romagnoli, Nicola Vianelli, Tiziana Lazzarotto, Michele Cavo, Francesca Palandri. Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity.
Leukemia research.
2022 05; 116(?):106819. doi:
10.1016/j.leukres.2022.106819. [PMID: 35303626] - Patrick Harrington, Katie J Doores, Jamie Saunders, Marc de Lord, Chandan Saha, Thomas Lechmere, Hataf Khan, Ho Pui Jeff Lam, Amy O' Reilly, Claire Woodley, Susan Asirvatham, Richard Dillon, Natalia Curto-Garcia, Jennifer O' Sullivan, Shahram Kordasti, Kavita Raj, Michael H Malim, Deepti Radia, Donal McLornan, Claire Harrison, Hugues de Lavallade. Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.
Blood cancer journal.
2022 04; 12(4):73. doi:
10.1038/s41408-022-00651-3. [PMID: 35459222] - Zhenghui Song, Xinhui Liu, Wan Zhang, Yue Luo, Hua Xiao, Yun Liu, Guanqi Dai, Jian Hong, Aimin Li. Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2.
Journal of translational medicine.
2022 04; 20(1):157. doi:
10.1186/s12967-022-03366-y. [PMID: 35382859] - Sean Bujarski, Christine Sutanto, Tanya M Spektor, Jennifer To, Regina A Swift, Tracy Green, Benjamin R Eades, Marsiye Emamy-Sadr, Eric Souther, James R Berenson. Use of serum B-cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone.
Hematological oncology.
2022 Apr; 40(2):243-248. doi:
10.1002/hon.2961. [PMID: 34982491] - Giovanni Caocci, Olga Mulas, Daniela Mantovani, Alessandro Costa, Andrea Galizia, Luca Barabino, Marianna Greco, Roberta Murru, Giorgio La Nasa. Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis.
Annals of hematology.
2022 04; 101(4):929-931. doi:
10.1007/s00277-021-04613-w. [PMID: 34302519] - Haris Ali, Ni-Chun Tsai, Timothy Synold, Sally Mokhtari, Weimin Tsia, Joycelynne Palmer, Tracey Stiller, Monzr Al Malki, Ibrahim Aldoss, Amandeep Salhotra, Syed Rahmanuddin, Vinod Pullarkat, Ji-Lian Cai, Anthony Stein, Stephen J Forman, Guido Marcucci, Matthew Mei, David S Snyder, Ryotaro Nakamura. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study.
Blood advances.
2022 03; 6(5):1444-1453. doi:
10.1182/bloodadvances.2021005035. [PMID: 34581764] - Mohamed E Shaker, Omnia M Hendawy, Mohamed El-Mesery, Sara H Hazem. The JAK inhibitor ruxolitinib abrogates immune hepatitis instigated by concanavalin A in mice.
International immunopharmacology.
2022 Feb; 103(?):108463. doi:
10.1016/j.intimp.2021.108463. [PMID: 34952468] - Roberto Ovilla-Martinez, Xochitl Cota-Rangel, Jose De La Peña-Celaya, Mariana Alejandra Alvarado-Zepeda, Alejandro Jiménez Sastré, Humberto Azuara Forcelledo, Bernardino Ordoñez Rodriguez, Juan Pulido Broca, Aaron Molina Jaimes, Alejandro Muñiz-Carvajal, Maria Magdalena Bahena García, Eduardo Cervera Ceballos, Nidia Paulina Zapata Canto, Jorge Oscar García Mendez, Omar Noel García Jímenez, Jesus Alberto Salas Heredia, Javier Solis Soto, Ruben Alberto Villalobos Mendez, Gregorio Ignacio Ibarra, Cindy Ledesma de la Cruz, Nora Araujo Martinez, Jessi Juárez Lara, Cecilio Omar Ceballos Zuñiga, Felipe Vicente Villaseñor Pérez, Jose Carlos Herrera Garcia, Patricia Nuche Salazar, Alfredo Dominguez Paregrina, Bertha Arizpe Bravo, Gabriela Enciso Figueroa, Teresita Trujillo, Adriana Miguel Álvarez, Diego de Jesús García Gallegos, Alejandro Ortiz Arroyo, Claudia Ivette Solorzano Soto, Hiram Javier Jaramillo Ramírez, Ibis De la Cruz Hernández, Sergio De Gante Martínez, Guadalupe Esmeralda Montesinos Gómez, Silvia Martínez Velasco, Roberto García Graullera, Miguel Angel Vázquez López, Victor Itaí Urbalejo Ceniceros, Yolanda Lugo García, Ana Itamar González Ávila, Jorge Duque Rodriguez, Rodolfo Ruiz Luján, Violeta I Rodríguez Rivera, Lucio Soberanes Ramírez, Pamela Elena Baez-Islas. Ruxolitinib as a treatment strategy for SARS-CoV-2 pneumonia: clinical experience in a real-world setting.
Journal of infection in developing countries.
2022 01; 16(1):63-72. doi:
10.3855/jidc.15126. [PMID: 35192523] - M Farouk Chughlay, Karen I Barnes, Myriam El Gaaloul, Nada Abla, Jörg J Möhrle, Paul Griffin, Paul van Giersbergen, Stephanie E Reuter, Hayley B Schultz, Anita Kress, Peter Tapley, Rebecca A Webster, Timothy Wells, James S McCarthy, Bridget E Barber, Louise Marquart, Michelle J Boyle, Christian R Engwerda, Stephan Chalon. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults.
Antimicrobial agents and chemotherapy.
2022 01; 66(1):e0158421. doi:
10.1128/aac.01584-21. [PMID: 34694880] - Vincent C Marconi, Carlee Moser, Christina Gavegnano, Steven G Deeks, Michael M Lederman, Edgar T Overton, Athe Tsibris, Peter W Hunt, Amy Kantor, Rafick-Pierre Sekaly, Randall Tressler, Charles Flexner, Selwyn J Hurwitz, Daniela Moisi, Brian Clagett, William R Hardin, Carlos Del Rio, Raymond F Schinazi, Jeffrey J Lennox. Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2022 01; 74(1):95-104. doi:
10.1093/cid/ciab212. [PMID: 33693561] - Wei-Ling Yan, Shi-Long Yang, Fen-Ying Zhao, Xiao-Jun Xu. Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2022 Jan; 28(1):222-227. doi:
10.1177/10781552211020821. [PMID: 34074166] - Yingxin Zhao, Peng Chen, Liping Dou, Fei Li, Meng Li, Lingmin Xu, Jing Chen, Mingyu Jia, Sai Huang, Nan Wang, Songhua Luan, Jinling Yang, Nan Bai, Daihong Liu. Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies.
Drug design, development and therapy.
2022; 16(?):817-825. doi:
10.2147/dddt.s354270. [PMID: 35370398] - O V Stanevich, D S Fomina, I G Bakulin, S I Galeev, E A Bakin, V A Belash, A N Kulikov, A A Lebedeva, D A Lioznov, Yu S Polushin, I V Shlyk, E A Vorobyev, S V Vorobyeva, T V Surovceva, N V Bakulina, M A Lysenko, I S Moiseev. Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study.
BMC infectious diseases.
2021 Dec; 21(1):1277. doi:
10.1186/s12879-021-06982-z. [PMID: 34937556] - Selwyn J Hurwitz, Sijia Tao, Christina Gavegnano, Yong Jiang, Randall L Tressler, Athe Tsibris, Carlos Del Rio, Edgar T Overton, Michael M Lederman, Amy Kantor, Carlee Moser, James J Kohler, Jeffrey Lennox, Vincent C Marconi, Charles W Flexner, Raymond F Schinazi. Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study.
Journal of clinical pharmacology.
2021 12; 61(12):1555-1566. doi:
10.1002/jcph.1930. [PMID: 34169526] - Tom Le Voyer, Cyril Gitiaux, François-Jérôme Authier, Christine Bodemer, Isabelle Melki, Pierre Quartier, Florence Aeschlimann, Arnaud Isapof, Jean Philippe Herbeuval, Vincent Bondet, Jean-Luc Charuel, Marie-Louise Frémond, Darragh Duffy, Mathieu P Rodero, Brigitte Bader-Meunier. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.
Rheumatology (Oxford, England).
2021 12; 60(12):5801-5808. doi:
10.1093/rheumatology/keab116. [PMID: 33576769] - M Emin Çorman, Ahmet Cetinkaya, Goksu Ozcelikay, Erdoğan Özgür, Esen B Atici, Lokman Uzun, Sibel A Ozkan. A porous molecularly imprinted nanofilm for selective and sensitive sensing of an anticancer drug ruxolitinib.
Analytica chimica acta.
2021 Dec; 1187(?):339143. doi:
10.1016/j.aca.2021.339143. [PMID: 34753569] - Alberto Picca, Nefeli Valyraki, Cristina Birzu, Nora Kramkimel, Olivier Hermine, Noel Zahr, Giulia Berzero, Dimitri Psimaras. Anti-Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors.
Neurology(R) neuroimmunology & neuroinflammation.
2021 11; 8(6):. doi:
10.1212/nxi.0000000000001073. [PMID: 34497101] - Paola Guglielmelli, Alessio Mazzoni, Laura Maggi, Seble Tekle Kiros, Lorenzo Zammarchi, Sofia Pilerci, Arianna Rocca, Michele Spinicci, Miriam Borella, Alessandro Bartoloni, Gian Maria Rossolini, Francesco Annunziato, Alessandro M Vannucchi. Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib.
American journal of hematology.
2021 11; 96(11):E408-E410. doi:
10.1002/ajh.26305. [PMID: 34331712] - Ching-Yi Chen, Wang-Chun Chen, Chi-Kuei Hsu, Chien-Ming Chao, Chih-Cheng Lai. Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials.
International immunopharmacology.
2021 Oct; 99(?):108027. doi:
10.1016/j.intimp.2021.108027. [PMID: 34343937] - Andreas Neubauer, Johannes Johow, Elisabeth Mack, Andreas Burchert, Damaris Meyn, Andrea Kadlubiec, Iuliu Torje, Hinnerk Wulf, Claus F Vogelmeier, Joachim Hoyer, Chrysanthi Skevaki, Ralf Michael Muellenbach, Christian Keller, Carmen Schade-Brittinger, Caroline Rolfes, Thomas Wiesmann. The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
Leukemia.
2021 10; 35(10):2917-2923. doi:
10.1038/s41375-021-01374-3. [PMID: 34385593] - Paloma Guisado Hernández, Pilar Blanco Lobo, Isabel Villaoslada, Beatriz de Felipe, José M Lucena, Guillermo Martín Gutierrez, María José Castro, Alicia Gutiérrez Valencia, María Isabel Sánchez Codez, Mirella Gaboli, Olaf Neth, Peter Olbrich. SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance?.
Journal of clinical immunology.
2021 10; 41(7):1502-1506. doi:
10.1007/s10875-021-01081-9. [PMID: 34109505] - Marcelo Iastrebner, Joaquín Castro, Edgardo García Espina, Carolina Lettieri, Silvio Payaslian, María Celia Cuesta, Pablo Gutiérrez Fernández, Araceli Mandrile, Angela Paola Contreras, Sebastián Gervasoni, Gabriel Verde, Cayetano Galetti, Estefanía Minoldo, Vanesa Caruso. Ruxolitinib in severe COVID-19: Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome.
Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina).
2021 09; 78(3):294-302. doi:
10.31053/1853.0605.v78.n3.32800. [PMID: 34617700] - Matthew J McConnell, Nao Kawaguchi, Reiichiro Kondo, Aurelio Sonzogni, Lisa Licini, Clarissa Valle, Pietro A Bonaffini, Sandro Sironi, Maria Grazia Alessio, Giulia Previtali, Michela Seghezzi, Xuchen Zhang, Alfred I Lee, Alexander B Pine, Hyung J Chun, Xinbo Zhang, Carlos Fernandez-Hernando, Hua Qing, Andrew Wang, Christina Price, Zhaoli Sun, Teruo Utsumi, John Hwa, Mario Strazzabosco, Yasuko Iwakiri. Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy.
Journal of hepatology.
2021 09; 75(3):647-658. doi:
10.1016/j.jhep.2021.04.050. [PMID: 33991637] - Chong-Xiang Chen, Jiao-Jiao Wang, Huan Li, Le-Tao Yuan, Robert Peter Gale, Yang Liang. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.
Leukemia.
2021 09; 35(9):2616-2620. doi:
10.1038/s41375-021-01266-6. [PMID: 33990684] - Annkristin Heine, Anna Maria Wolf, Sebastian Schlaweck, Solveig Nora Daecke, Peter Brossart, Dominik Wolf. Pacritinib protects dendritic cells more efficiently than ruxolitinib.
Experimental hematology.
2021 08; 100(?):37-40. doi:
10.1016/j.exphem.2021.06.004. [PMID: 34182006] - Xueshi Chen, Cheng Gao, Ya'nan Yan, Zhiqi Cheng, Guang Chen, Tongyu Rui, Chengliang Luo, Yuan Gao, Tao Wang, Xiping Chen, Luyang Tao. Ruxolitinib exerts neuroprotection via repressing ferroptosis in a mouse model of traumatic brain injury.
Experimental neurology.
2021 08; 342(?):113762. doi:
10.1016/j.expneurol.2021.113762. [PMID: 33991524] - Xiaohua Gong, Xuejun Chen, Michael E Kuligowski, Xing Liu, Xiang Liu, Evan Cimino, Ryan McGee, Swamy Yeleswaram. Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies.
American journal of clinical dermatology.
2021 Jul; 22(4):555-566. doi:
10.1007/s40257-021-00610-x. [PMID: 33982267] - Mo'tasem M Alsmadi, Nour M Al-Daoud, Mays M Jaradat, Saja B Alzughoul, Amani D Abu Kwiak, Salam S Abu Laila, Ayat J Abu Shameh, Mohammad K Alhazabreh, Sana'a A Jaber, Hala T Abu Kassab. Physiologically-based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment.
Biopharmaceutics & drug disposition.
2021 Jun; 42(6):263-284. doi:
10.1002/bdd.2282. [PMID: 33904202] - Raffaele Badolato, Marco Cattalini, Rosaria Scaduto, Sara Roversi, Jessica Galli, Rosalba Monica Ferraro, Manuela Cortesi, Simona Orcesi, Silvia Giliani, Elisa Fazzi. IFN-α levels in ruxolitinib-treatead Aicardi-Goutières patient during SARS-CoV-2 infection: A case report.
Clinical immunology (Orlando, Fla.).
2021 06; 227(?):108743. doi:
10.1016/j.clim.2021.108743. [PMID: 33930555] - ZhiGang Wang, YongQun He, Jing Huang, XiaoLin Yang. Integrative web-based analysis of omics data for study of drugs against SARS-CoV-2.
Scientific reports.
2021 05; 11(1):10763. doi:
10.1038/s41598-021-89578-6. [PMID: 34031435] - Lorenzo Iovino, Laurel A Thur, Sacha Gnjatic, Aude Chapuis, Filippo Milano, Joshua A Hill. Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy.
Journal for immunotherapy of cancer.
2021 05; 9(5):. doi:
10.1136/jitc-2021-002392. [PMID: 33986127] - Andrea Mortara, Simone Mazzetti, Davide Margonato, Pietro Delfino, Chiara Bersano, Francesco Catagnano, Marinella Lauriola, Paolo Grosso, Gianluca Perseghin, Giovanbattista Ippoliti. Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation.
Clinical and translational science.
2021 05; 14(3):1062-1068. doi:
10.1111/cts.12971. [PMID: 33403775] - Farzan Solimani, Katharina Meier, Kamran Ghoreschi. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.
European journal of immunology.
2021 05; 51(5):1071-1075. doi:
10.1002/eji.202149173. [PMID: 33675065] - E Caradec, D Mouren, M Zrounba, L-D Azoulay, C Blandin, S Ivanoff, V Levy, P-Y Brillet, H Nunes, Y Uzunhan. COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib.
Respiratory medicine and research.
2021 05; 79(?):100799. doi:
10.1016/j.resmer.2020.100799. [PMID: 33242734] - Sarah Hansen, Waleed Alduaij, Catherine M Biggs, Sara Belga, Kai Luecke, Hayley Merkeley, Luke Y C Chen. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
European journal of haematology.
2021 May; 106(5):654-661. doi:
10.1111/ejh.13593. [PMID: 33523540] - Anna Materna-Kiryluk, Agnieszka Pollak, Karol Gawalski, Aleksandra Szczawinska-Poplonyk, Zuzanna Rydzynska, Anna Sosnowska, Bożena Cukrowska, Piotr Gasperowicz, Ewa Konopka, Barbara Pietrucha, Tomasz M Grzywa, Magdalena Banaszak-Ziemska, Marek Niedziela, Jolanta Skalska-Sadowska, Piotr Stawiński, Dariusz Śladowski, Dominika Nowis, Rafal Ploski. Mosaic IL6ST variant inducing constitutive GP130 cytokine receptor signaling as a cause of neonatal onset immunodeficiency with autoinflammation and dysmorphy.
Human molecular genetics.
2021 04; 30(3-4):226-233. doi:
10.1093/hmg/ddab035. [PMID: 33517393] - Dingding Gao, Nan Jin, Yixian Fu, Yueyue Zhu, Yujie Wang, Ting Wang, Yuehong Chen, Mingming Zhang, Qiang Xiao, Min Huang, Yingxia Li. Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors.
European journal of medicinal chemistry.
2021 Apr; 216(?):113333. doi:
10.1016/j.ejmech.2021.113333. [PMID: 33689932] - Nikhil Vergis, Rachel Phillips, Victoria Cornelius, Alexia Katsarou, Taryn Youngstein, Lucy Cook, Michelle Willicombe, Clio Pilay, Tina Shturova, Melanie Almonte, Asad Charania, Richard Turner, Onn Min Kon, Graham Cooke, Mark Thursz, Svetlana Cherlin, James Wason, Dragana Milojkovic, Andew J Innes, Nichola Cooper. Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.
Trials.
2021 Apr; 22(1):270. doi:
10.1186/s13063-021-05190-z. [PMID: 33845867] - Alessandro M Vannucchi, Benedetta Sordi, Alessandro Morettini, Carlo Nozzoli, Loredana Poggesi, Filippo Pieralli, Alessandro Bartoloni, Alessandro Atanasio, Filippo Miselli, Chiara Paoli, Giuseppe G Loscocco, Andrea Fanelli, Ombretta Para, Andrea Berni, Irene Tassinari, Lorenzo Zammarchi, Laura Maggi, Alessio Mazzoni, Valentina Scotti, Giorgia Falchetti, Danilo Malandrino, Fabio Luise, Giovanni Millotti, Sara Bencini, Manuela Capone, Marie Pierre Piccinni, Francesco Annunziato, Paola Guglielmelli. Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.
Leukemia.
2021 04; 35(4):1121-1133. doi:
10.1038/s41375-020-01018-y. [PMID: 32814839] - Kristina Maas-Bauer, Chrissoula Kiote-Schmidt, Hartmut Bertz, Petya Apostolova, Ralph Wäsch, Gabriele Ihorst, Jürgen Finke, Robert Zeiser. Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease.
Bone marrow transplantation.
2021 04; 56(4):909-916. doi:
10.1038/s41409-020-01122-8. [PMID: 33203951] - Manuela Spadea, Francesca Carraro, Francesco Saglio, Elena Vassallo, Rosanna Pessolano, Massimo Berger, Carlo Scolfaro, Sergio Grassitelli, Franca Fagioli. Successfully treated severe COVID-19 and invasive aspergillosis in early hematopoietic cell transplantation setting.
Transplant infectious disease : an official journal of the Transplantation Society.
2021 04; 23(2):e13470. doi:
10.1111/tid.13470. [PMID: 32959932] - Tiziano Barbui, Alessandra Carobbio. Response to: Ruxolitinib withdrawal due to the COVID-19.
Leukemia.
2021 04; 35(4):1219. doi:
10.1038/s41375-021-01187-4. [PMID: 33633312] - Illias Tazi. [Antineoplasic drug repurposing in hematology for COVID-19 treatment].
Bulletin du cancer.
2021 Apr; 108(4):435-437. doi:
10.1016/j.bulcan.2020.12.009. [PMID: 33663776] - Marko Lucijanic, Rajko Kusec. Ruxolitinib withdrawal due to the COVID-19.
Leukemia.
2021 04; 35(4):1218. doi:
10.1038/s41375-021-01214-4. [PMID: 33731851] - Philip S Boonstra, Asra Ahmed, Samuel A Merrill, Ryan A Wilcox. Ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis.
American journal of hematology.
2021 04; 96(4):E103-E105. doi:
10.1002/ajh.26091. [PMID: 33428805] - Arnaud Bruyère, Marc Le Vée, Elodie Jouan, Stephanie Molez, Anne T Nies, Olivier Fardel. Differential in vitro interactions of the Janus kinase inhibitor ruxolitinib with human SLC drug transporters.
Xenobiotica; the fate of foreign compounds in biological systems.
2021 Apr; 51(4):467-478. doi:
10.1080/00498254.2021.1875516. [PMID: 33455503] - E Díaz, R Amézaga Menéndez, P Vidal Cortés, M G Escapa, B Suberviola, A Serrano Lázaro, P Marcos Neira, M Quintana Díaz, M Catalán González. [Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].
Medicina intensiva.
2021 Mar; 45(2):104-121. doi:
10.1016/j.medin.2020.06.017. [PMID: 32854988] - Francesco Saraceni, Ilaria Scortechini, Giorgia Mancini, Marianna Mariani, Irene Federici, Mariana Gaetani, Paolo Barbatelli, Maria Luisa Minnucci, Patrizia Bagnarelli, Attilio Olivieri. Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.
Transplant infectious disease : an official journal of the Transplantation Society.
2021 Feb; 23(1):e13401. doi:
10.1111/tid.13401. [PMID: 32629531] - Yordan Khaedir, Rona Kartika. Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
2021 02; 41(2):37-43. doi:
10.1089/jir.2020.0135. [PMID: 33621130] - Tiziano Barbui, Alessandro Maria Vannucchi, Alberto Alvarez-Larran, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Alberto Ferrari, Giuseppe Rossi, Elena Elli, Marcio Miguel Andrade-Campos, Mercedes Gasior Kabat, Jean-Jaques Kiladjian, Francesca Palandri, Giulia Benevolo, Valentin Garcia-Gutierrez, Maria Laura Fox, Maria Angeles Foncillas, Carmen Montoya Morcillo, Elisa Rumi, Santiago Osorio, Petros Papadopoulos, Massimiliano Bonifacio, Keina Susana Quiroz Cervantes, Miguel Sagues Serrano, Gonzalo Carreno-Tarragona, Marta Anna Sobas, Francesca Lunghi, Andrea Patriarca, Begona Navas Elorza, Anna Angona, Elena Magro Mazo, Steffen Koschmieder, Marco Ruggeri, Beatriz Cuevas, Juan Carlos Hernandez-Boluda, Emma Lopez Abadia, Blanca Xicoy Cirici, Paola Guglielmelli, Marta Garrote, Daniele Cattaneo, Rosa Daffini, Fabrizio Cavalca, Beatriz Bellosillo, Lina Benajiba, Natalia Curto-Garcia, Marta Bellini, Silvia Betti, Valerio De Stefano, Claire Harrison, Alessandro Rambaldi. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.
Leukemia.
2021 02; 35(2):485-493. doi:
10.1038/s41375-020-01107-y. [PMID: 33414483] - Gilles Kaplanski, Denis Bontemps, Pierre Esnault, Valery Blasco, Julien Carvelli, David Delarbre, Raphael Cauchois, Jean-Marie Forel, Laurent Papazian. Combined Anakinra and Ruxolitinib treatment to rescue extremely ill COVID-19 patients: A pilot study.
Autoimmunity reviews.
2021 Feb; 20(2):102726. doi:
10.1016/j.autrev.2020.102726. [PMID: 33326855] - A D'Alessio, P Del Poggio, F Bracchi, G Cesana, N Sertori, D Di Mauro, A Fargnoli, M Motta, C Giussani, P Moro, G Vitale, M Giacomini, G Borra. Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia.
Leukemia.
2021 02; 35(2):635-638. doi:
10.1038/s41375-020-01087-z. [PMID: 33173161] - Naruemit Sayabovorn, Piriyaporn Chongtrakool, Methee Chayakulkeeree. Cryptococcal fungemia and Mycobacterium haemophilum cellulitis in a patient receiving ruxolitinib: a case report and literature review.
BMC infectious diseases.
2021 Jan; 21(1):27. doi:
10.1186/s12879-020-05703-2. [PMID: 33413168] - Patricio Rojas, Mauricio Sarmiento. JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients.
Acta haematologica.
2021; 144(3):314-318. doi:
10.1159/000510179. [PMID: 32726783] - Eeda Koti Reddy, Srisravanthi Battula, Shaik Anwar, Ayyiliath M Sajith. Drug Re-purposing Approach and Potential Therapeutic Strategies to Treat COVID-19.
Mini reviews in medicinal chemistry.
2021; 21(6):704-723. doi:
10.2174/1389557520666201113105940. [PMID: 33185159] - Mauricio Sarmiento, Patricio Rojas, Joaquin Jerez, Pablo Bertín, James Campbell, Maria J García, Jaime Pereira, Nicolas Triantafilo, Mauricio Ocqueteau. Ruxolitinib for Severe COVID-19-Related Hyperinflammation in Nonresponders to Steroids.
Acta haematologica.
2021 ; 144(6):620-626. doi:
10.1159/000516464. [PMID: 34111867] - Felicitas La Rosée, Paul La Rosée. Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies.
Acta haematologica.
2021; 144(3):246-249. doi:
10.1159/000510770. [PMID: 32818929] - Baransel Kamaz, Ann Mullally. COVID-19 and myeloproliferative neoplasms: some considerations.
Leukemia.
2021 01; 35(1):279-281. doi:
10.1038/s41375-020-01070-8. [PMID: 33106624] - Marco Santoro, Cristina Rotolo, Vincenzo Accurso, Ilaria Morreale, Salvatrice Mancuso, Sergio Siragusa. Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literature.
Chemotherapy.
2021; 66(3):87-91. doi:
10.1159/000515430. [PMID: 33784668] - Vincenzo Sammartano, Adele Santoni, Bruno Frediani, Anna Sicuranza, Cencini Emanuele, Federico Franchi, Enrico Capochiani, Monica Bocchia. Efficacy and safety of ruxolitinib for Covid-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant).
Leukemia & lymphoma.
2020 12; 61(14):3523-3525. doi:
10.1080/10428194.2020.1817440. [PMID: 32902339] - Hailan Li, Huaping Liu. Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19.
The Journal of allergy and clinical immunology.
2020 12; 146(6):1453. doi:
10.1016/j.jaci.2020.09.002. [PMID: 32980157] - Yang Cao, Jia Wei, Gaoxiang Wang, Liting Chen, Hui Luo, Jianfeng Zhou. Reply.
The Journal of allergy and clinical immunology.
2020 12; 146(6):1453-1454. doi:
10.1016/j.jaci.2020.07.037. [PMID: 32980158] - Indushekhar Persaud, Sharon Diamond, Rina Pan, Krista Burke, Jennifer Harris, Michelle Conlin, Swamy Yeleswaram. Plasma pharmacokinetics and distribution of ruxolitinib into skin following oral and topical administration in minipigs.
International journal of pharmaceutics.
2020 Nov; 590(?):119889. doi:
10.1016/j.ijpharm.2020.119889. [PMID: 32949620] - Marianna Parlato, Qing Nian, Fabienne Charbit-Henrion, Frank M Ruemmele, Fernando Rodrigues-Lima, Nadine Cerf-Bensussan. Loss-of-Function Mutation in PTPN2 Causes Aberrant Activation of JAK Signaling Via STAT and Very Early Onset Intestinal Inflammation.
Gastroenterology.
2020 11; 159(5):1968-1971.e4. doi:
10.1053/j.gastro.2020.07.040. [PMID: 32721438] - Steffen Koschmieder, Edgar Jost, Christian Cornelissen, Tobias Müller, Maximilian Schulze-Hagen, Johannes Bickenbach, Gernot Marx, Michael Kleines, Nikolaus Marx, Tim H Brümmendorf, Michael Dreher. Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis.
European journal of haematology.
2020 Nov; 105(5):655-658. doi:
10.1111/ejh.13480. [PMID: 32593209] - Francine M Foss, Ami Rubinowitz, Marie L Landry, Iris Isufi, Lohith Gowda, Stuart Seropian, Sarah Perreault, Sheela V Shenoi. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib.
Clinical lymphoma, myeloma & leukemia.
2020 11; 20(11):720-723. doi:
10.1016/j.clml.2020.06.014. [PMID: 32727701] - Ulrike Felgenhauer, Andreas Schoen, Hans Henrik Gad, Rune Hartmann, Andreas R Schaubmar, Klaus Failing, Christian Drosten, Friedemann Weber. Inhibition of SARS-CoV-2 by type I and type III interferons.
The Journal of biological chemistry.
2020 10; 295(41):13958-13964. doi:
10.1074/jbc.ac120.013788. [PMID: 32587093] - Jiongjiong Wang, Richard A Prinz, Xiufan Liu, Xiulong Xu. In Vitro and In Vivo Antiviral Activity of Gingerenone A on Influenza A Virus Is Mediated by Targeting Janus Kinase 2.
Viruses.
2020 10; 12(10):. doi:
10.3390/v12101141. [PMID: 33050000] - V Yu Mareev, Ya A Orlova, E P Pavlikova, Z A Akopyan, S T Matskeplishvili, A G Plisyk, E M Seredenina, A V Potapenko, P S Malakhov, L M Samokhodskaya, Е А Mershina, V E Sinitsyn, D A Asratyan, E A Zhdanova, Yu V Mareev, Yu L Begrambekova, E A Shatochina, А А Kamalov. [Proactive anti-inflammatory and anticoagulant therapy in the treatment of advanced stages of novel coronavirus infection (COVID-19). Case Series and Study Design: COLchicine versus ruxolitinib and secukinumab in open prospective randomIzed trial (COLORIT)].
Kardiologiia.
2020 Oct; 60(9):4-21. doi:
10.18087/cardio.2020.9.n1338. [PMID: 33131470] - Zita-Rose Manjaly Thomas, Anne Leuppi-Taegtmeyer, Dagmar Jamiolkowski, Esther Steveling-Klein, Felicitas Bellutti-Enders, Kathrin Scherer Hofmeier, Karin Hartmann. Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
The Journal of allergy and clinical immunology.
2020 10; 146(4):786-789. doi:
10.1016/j.jaci.2020.07.008. [PMID: 32710973] - Massimo Breccia, Alfonso Piciocchi, Valerio De Stefano, Guido Finazzi, Alessandra Iurlo, Paola Fazi, Stefano Soddu, Bruno Martino, Francesca Palandri, Sergio Siragusa, Francesco Albano, Francesco Passamonti, Marco Vignetti, Alessandro M Vannucchi. COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey.
Leukemia.
2020 10; 34(10):2813-2814. doi:
10.1038/s41375-020-01032-0. [PMID: 32843716] - Alessandro Gozzetti, Enrico Capochiani, Monica Bocchia. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19.
Leukemia.
2020 10; 34(10):2815-2816. doi:
10.1038/s41375-020-01038-8. [PMID: 32879427] - Lia Phillips, Jovana Pavisic, Dominder Kaur, N Valerio Dorrello, Larisa Broglie, Nobuko Hijiya. Successful management of SARS-CoV-2 acute respiratory distress syndrome and newly diagnosed acute lymphoblastic leukemia.
Blood advances.
2020 09; 4(18):4358-4361. doi:
10.1182/bloodadvances.2020002745. [PMID: 32926122] - Swamy Yeleswaram, Paul Smith, Timothy Burn, Maryanne Covington, Ashish Juvekar, Yanlong Li, Peg Squier, Peter Langmuir. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Clinical immunology (Orlando, Fla.).
2020 09; 218(?):108517. doi:
10.1016/j.clim.2020.108517. [PMID: 32585295] - Guang-Qiang Meng, Jing-Shi Wang, Wen-Yuan Lai, Yue Song, Zhuo Gao, Shuo Meng, Jia Zhang, Yi-Ni Wang, Zhao Wang. [Establishment of Secondary HLH Mouse Model and Effect of Ruxolitinib on Disease Manifestations of Model Mide].
Zhongguo shi yan xue ye xue za zhi.
2020 Aug; 28(4):1376-1380. doi:
10.19746/j.cnki.issn.1009-2137.2020.04.050. [PMID: 32798429] - Bakiye Goker Bagca, Cigir Biray Avci. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
Cytokine & growth factor reviews.
2020 08; 54(?):51-62. doi:
10.1016/j.cytogfr.2020.06.013. [PMID: 32636055] - Sophie Portsmore, Thien Ngoc Tran Nguyen, Emma Beacham, Pratap Neelakantan. Combined IL-6 and JAK/STAT inhibition therapy in COVID-19-related sHLH, potential game changer.
British journal of haematology.
2020 08; 190(4):525-528. doi:
10.1111/bjh.16966. [PMID: 32584421] - Andrew J Innes, Lucy B Cook, Sasha Marks, Edward Bataillard, Christina Crossette-Thambiah, Gayathiri Sivasubramaniam, Jane Apperley, Dragana Milojkovic. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.
British journal of haematology.
2020 08; 190(4):e198-e200. doi:
10.1111/bjh.16979. [PMID: 32593183] - Valeria Gaspari, Corrado Zengarini, Sonia Greco, Valeria Vangeli, Antonio Mastroianni. Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports.
International journal of antimicrobial agents.
2020 Aug; 56(2):106023. doi:
10.1016/j.ijantimicag.2020.106023. [PMID: 32450201] - Andreas Neubauer, Thomas Wiesmann, Claus F Vogelmeier, Elisabeth Mack, Chrysanthi Skevaki, Christine Gaik, Christian Keller, Jens Figiel, Kristina Sohlbach, Caroline Rolfes, Harald Renz, Hinnerk Wulf, Andreas Burchert. Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
Leukemia.
2020 08; 34(8):2276-2278. doi:
10.1038/s41375-020-0907-9. [PMID: 32555296] - Motoharu Shibusawa, Tetsuya Tanimoto. Long-term efficacy and safety of ruxolitinib in polycythaemia vera.
The Lancet. Haematology.
2020 07; 7(7):e505-e506. doi:
10.1016/s2352-3026(20)30102-2. [PMID: 32589972] - F La Rosée, H C Bremer, I Gehrke, A Kehr, A Hochhaus, S Birndt, M Fellhauer, M Henkes, B Kumle, S G Russo, P La Rosée. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
Leukemia.
2020 07; 34(7):1805-1815. doi:
10.1038/s41375-020-0891-0. [PMID: 32518419] - Giovanni Caocci, Giorgio La Nasa. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?.
Annals of hematology.
2020 Jul; 99(7):1675-1676. doi:
10.1007/s00277-020-04067-6. [PMID: 32405693] - Yang Cao, Jia Wei, Liang Zou, Tiebin Jiang, Gaoxiang Wang, Liting Chen, Liang Huang, Fankai Meng, Lifang Huang, Na Wang, Xiaoxi Zhou, Hui Luo, Zekai Mao, Xing Chen, Jungang Xie, Jing Liu, Hui Cheng, Jianping Zhao, Gang Huang, Wei Wang, Jianfeng Zhou. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.
The Journal of allergy and clinical immunology.
2020 Jul; 146(1):137-146.e3. doi:
10.1016/j.jaci.2020.05.019. [PMID: 32470486] - F Heidel, A Hochhaus. Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.
Leukemia.
2020 07; 34(7):1723-1725. doi:
10.1038/s41375-020-0898-6. [PMID: 32528040] - Samuel Strohbehn, Harish Seethapathy, Nifasha Rusibamayila, Ian Strohbehn, Meghan Lee, Gabriela Hobbs, Alla Keyzner, Kenar D Jhaveri, Meghan E Sise. Acute kidney injury after ruxolitinib: Common complication, uncommon cause.
American journal of hematology.
2020 07; 95(7):E181-E183. doi:
10.1002/ajh.25804. [PMID: 32239674] - Zhe Wang, Xiaoyu Wang, Yaqin Jia, Hang Yin, Yuyi Feng, Lili Jiang, Jun Cao, Yong Liu. Inhibition of human UDP-glucuronosyltransferase enzymes by midostaurin and ruxolitinib: implications for drug-drug interactions.
Biopharmaceutics & drug disposition.
2020 Jun; 41(6):231-238. doi:
10.1002/bdd.2241. [PMID: 32436276] - NULL. COVID-19 remedies.
Nature biomedical engineering.
2020 06; 4(6):575-576. doi:
10.1038/s41551-020-0579-9. [PMID: 32533125] - Danielle Peterson, William Damsky, Brett King. The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Journal of the American Academy of Dermatology.
2020 06; 82(6):e223-e226. doi:
10.1016/j.jaad.2020.03.099. [PMID: 32278797] - Marco Malavolta, Robertina Giacconi, Dario Brunetti, Mauro Provinciali, Fabrizio Maggi. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats.
Cells.
2020 04; 9(4):. doi:
10.3390/cells9040909. [PMID: 32276453] - Xilan Yang, Jian Jia, Zhen Yu, Zheng Duanmu, Huiwei He, Sen Chen, Chen Qu. Inhibition of JAK2/STAT3/SOCS3 signaling attenuates atherosclerosis in rabbit.
BMC cardiovascular disorders.
2020 03; 20(1):133. doi:
10.1186/s12872-020-01391-7. [PMID: 32169038] - Daisuke Tsukui, Hiroaki Fujita, Keisuke Suzuki, Koichi Hirata. A case report of cryptococcal meningitis associated with ruxolitinib.
Medicine.
2020 Mar; 99(13):e19587. doi:
10.1097/md.0000000000019587. [PMID: 32221077] - Stephan Wilmes, Maximillian Hafer, Joni Vuorio, Julie A Tucker, Hauke Winkelmann, Sara Löchte, Tess A Stanly, Katiuska D Pulgar Prieto, Chetan Poojari, Vivek Sharma, Christian P Richter, Rainer Kurre, Stevan R Hubbard, K Christopher Garcia, Ignacio Moraga, Ilpo Vattulainen, Ian S Hitchcock, Jacob Piehler. Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations.
Science (New York, N.Y.).
2020 02; 367(6478):643-652. doi:
10.1126/science.aaw3242. [PMID: 32029621] - Alican Kusoglu, Bakiye G Bagca, Neslihan P O Ay, Guray Saydam, Cigir B Avci. Ruxolitinib Regulates the Autophagy Machinery in Multiple Myeloma Cells.
Anti-cancer agents in medicinal chemistry.
2020; 20(18):2316-2323. doi:
10.2174/1871520620666200218105159. [PMID: 32067619] - Malak Ali Alghamdi, Jaazeel Mulla, Narjes Saheb Sharif-Askari, Francisco J Guzmán-Vega, Stefan T Arold, Mervat Abd-Alwahed, Nasser Alharbi, Tarek Kashour, Rabih Halwani. A Novel Biallelic STING1 Gene Variant Causing SAVI in Two Siblings.
Frontiers in immunology.
2020; 11(?):599564. doi:
10.3389/fimmu.2020.599564. [PMID: 33488593]